ATTORNEY'S DKT NO. APPLICATION NO. Substitute for form 1449A/PTO 003300-816 09/890,949 U.S. PATENT DOCUMENTS

Patentee or Applicant

Patentee or Applicant

(MM-DD-YYYY) INFORMATION DISCLOSURE STATEMENT BY APPLICANT NOV 2 9 2001 Patent Document Kind Code Examine Initials Number (if known) FOREIGN PATENT DOCUMENTS Foreign Patent Document Examiner Kind Code Date of Publication Translation (MM-DD-YYYY) no ∧Initials Number (if known) Country Yes WO 98/22509 **PCT** 05/1998 Α1 2-236452 09/1990 Japan NON PATENT LITERATURE DOCUMENTS Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials publisher, city and/or country where published. Kenneth A. Bauer et al., "Detection of Protein C Activation in Humans," J. Clinical Invest. The American Society for Clinical Investigation, Inc., Vol. 74 (1984) pp. 2033-2041 András Gruber et al., "Direct Detection of Activated Protein C in Blood From Human Subjects," Blood, Vol 79, No. 9 (1992) pp. 2340-2348 Francisco España et al. "Quantification of Circulating Activated Protein C in Human Plasma by Immunoassays - Enzyme Levels are Proportional to Total Protein C Levels," Thrombosis and Haemostasis - F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 75 (1) (1996) pp. 56-61 Francisco España et al. "Determination of Functional and Antigenic Protein C Inhibitor and Its Complexes with Activated Protein C in Plasma by Elisa's," Thrombosis Research, Vol 55 (1989) PP. 671-682 Francisco España et al. "Determination of Plasma Protein C Inhibitor and of Two Activated Protein C-Inhibitor Complexes in Normals and in Patients with Intravascular Coagulation and Thrombotic Disease," Thrombosis Research Vol. 59 (1990) PP.593-608 Kouzou Minamikawa et al. "Increased Activated Protein C-Protein C Inhibitor Complex Levels in Patients with Pulmonary Embolism," Thrombosis and Haemostasis- F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 71 (2) (1994) pp. 192-194 Martin Laurell et al., "Monoclonal Antibodies Against the Heparin-Dependent Protein C Inhibitor Suitable for Inhibitor Purification and Assay of Inhibitor Complexes," Thrombosis and Haemostasis - F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 60 (2) (1988) pp. 334-339 Ariane de Agostini et al., "A Common Neoepitope is Created When the Reactive Center of C1-Inhibitor is Cleaved by Plasma Kallikrein, Activated Factor XII Fragment, C1 Esterase, or Neutriphil Elastase," J. Clin. Invest, Vol. 82 (1988) Shinji Asakura et al., "A Monoclonal Antibody That Triggers Deacylation of an Intermediate Thrombin-Antithrombin III Complex," The Journal of Biological Chemistry, Vol 264, No. 23, (1989) pp. 13736-13739 Ingemar Björk *et al.*, "Immunologic Evidence for Insertion of the Reactive-Bond Loop of Antithrombin into the A β-Sheet of the Inhibitor During Trapping of Target Proteinases," Biochemistry, Vol. 32, (1993) pp. 6501-6505 Examiner Date

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Considered

Signature

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.
003300-816	09/890,949
APPLICANT	-
Johan STENFLO	
FILING DATE	GROUP
Sentember 10, 2001	1645

NOV 2 9	2001	nine: 12	U.S. PATENT DOCUM	TENTS			
(Tr.	U.S. Patent	gillegilbliot of XXXXIIIIIII bissies		and the block has been been been been been been been bee	.281_G/martidesCrop#HighlidusBullo.de, b255;phys.bbsc2026.3/h	- CONTROL OF STREET	
EXAMINEN	110	Kind Code	Name of Patentee or Applicant		Date of Pul	blication	
Initials	Number	(if known)	of Cited Document		(MM-DD-	MOV 3 0 2007  H CENTER 1600/2900	
					REA		
						1	
					· No.	VEN	
	<del>                                     </del>	+			150, 30	~	
					CENT CENT	01	
		<del>   </del>			EN 160	- /	
		ļ			. , , 000/	20/10	
						-000	
	<del></del>						
		-	DEIGN PATENT DOG	INSERITO			
	KOKA MANGALA MANGALA NA NA NASALAKITAN MANGA	(\$12400425-00-20-002325-000000000000000000000000	REIGN PATENT DOC	JIVIEIVI O			
F	Foreign Paten				Date of Publication	Translation	
Examiner Initials	Number	Kind Code (if known)	Country		(MM-DD-YYYY)	Yes no	
			· · · · · · · · · · · · · · · · · · ·				
		1					
		1					
		NONE	ATENT LITERATURE I	OCCUMEN	ITC .		
operajeni si ye sala	el et Tolle Calle abbeed T		No the last term of the	ALTERNATION INCOMES TO CONTRACT	TO SHARM THE CHIEF AND A SECTION OF THE CHIEF AN		
Examiner					ile (when appropriate), title o ate, page(s), volume-issue nu		
Initials	Kom (soo.	., magazmo, journ	publisher, city and/or cour				
					rmal Growth Factor Precurso		
1 7 F		nd a Monoclonal	Antibody," The Journal of	Biological Ch	nemistry, Vol. 262, No. 28, (	1987) pp.	
	13798-13804  Carl A.K. Borrebaeck <i>et al.</i> , "Production and Characterization of a Monoclonal Antibody Against the Seed Lectin of the						
· ·						ed Lectin or the	
1 3	Dolichos biflorus Plant," The Journal of Biological Chemistry, Vol. 256, No. 10, (1981) pp. 4723-4725  Martin Laurell et al., "Protein C Inhibitor in Human Body Fluids," The American Society for Clinical Investigation, Inc.						
	Vol. 89, (1992) pp. 1094-1101						
					ent Protein S Fully Contained		
L 3// *	Ferminal Laminin-G-type Repeats. A Study Using Recombinant Factor IX-Protein S Chimeras and Surface Plasmon Resonance," <i>Biochemistry</i> Vol. 36, No. 12, (1997) pp. 3745-3754						
<b>├</b>	2.500.10.1007		, (, pp. 0. 10 0				
1 -							
Examiner	( ), )	Λ . Λ		Date	11/ /	· · · · · · · · · · · · · · · · · · ·	
Signature	JH1~	~ }) U~		Considered	1/16/03		
		<del></del>			<del></del>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.